Bevyxxa™ (betrixaban) – New drug approval
June 23, 2017 – The FDA announced the approval of Portola Pharmaceuticals’ Bevyxxa (betrixaban) for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
Top